In This Episode
Novavax’s vaccine has shown 89 per cent efficacy in UK trials. The government has bought 60 million doses of the jab, and it’s expected that production will begin in Teesside later this year. But, as the EU’s rollout languishes and their row with AstraZeneca escalates, should Britain consider giving away its vaccines? Katy Balls speaks to James Forsyth and Fraser Nelson.
Comments
Black Friday sale: Get 10 weeks for just $1
Unlimited access to the The Spectator, online and via the app
SUBSCRIBE NOW Just $1 for 10 weeksAlready a subscriber? Log in